Even though the number of studied cases remains small, PET also has the prospect of successful use in monitoring disease (e.g., PARP‐targeted PET), monitoring therapeutic effects (e.g., FLT PET), predicting which patients are prone to therapy resistance (e.g., CXCR4 PET), and non‐invasively identifying patients who could benefit from novel pharmacological treatments (e.g., FES PET), while targeted radionuclide therapy has high potential for future clinical treatment in ovarian cancer. The gene discussed is PARP1; the disease is ovarian carcinoma.